Company intelligence / Profile preview

Enzon Pharmaceuticals

Cranford, New Jersey, United Statesenzon.com ↗

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

Enzon Pharmaceuticals is currently positioned as a public company acquisition vehicle with limited operations. Previously, it had marketed products including PegIntron, and had conducted clinical trials for various compounds including PEG-SN38 which showed notable activity in patients with previously treated metastatic breast cancer.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: PEGylated therapeuticsmRNA antagonists
Industry: Investors

Drug pipeline

3 assets

pegaspargase

Commercial

Indications: Lymphoma, Acute lymphoblastic leukemia

2 more assets in the full pipeline.

Request access →

Partnerships

Micromet AGsigma-tau Grouppartnership in China for PEGylation technology

Beyond the preview

Go deeper on Enzon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzon Pharmaceuticals.

Explore the full profile